ANI Pharmaceuticals, Inc.
Financials
Valuation Metrics
ANI Pharmaceuticals, Inc.'s Market Cap is $1.82B. At end of 2025 it was $1.58B. Ranked #2116 of 3,111 in US market (top 68%), #819 of 1,445 on NASDAQ (top 57%), #146 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.82B | US#2,116/3,111 Sec#146/269 |
| Revenue | $924M | US#1,991/3,111 Sec#55/269 |
| Net Income | $90M | US#1,651/3,111 Sec#58/269 |
| Total Assets | $1.42B | US#2,273/3,111 Sec#71/269 |
| Net Assets | $562M | US#2,172/3,111 Sec#104/269 |
| Employees | 970 | US#1,268/3,111 Sec#34/269 |
| Value | ||
| P/E | 20.30x | US#1,051/3,111 Sec#38/269 |
| P/B | 3.24x | US#1,783/3,111 Sec#96/269 |
| PEG | 0.23x | US#345/3,111 Sec#16/269 |
| P/S | 1.97x | US#1,250/3,111 Sec#31/269 |
| EV/EBITDA | 7.82x | US#453/3,111 Sec#16/269 |
| FCF Yield | 8.81% | US#617/3,111 Sec#21/269 |
| Profitability | ||
| ROE | 15.95% | US#798/3,111 Sec#44/269 |
| ROA | 6.31% | US#821/3,111 Sec#48/269 |
| Op. Margin | 13.38% | US#1,347/3,111 Sec#55/269 |
| Revenue Growth | 20.46% | US#726/3,111 Sec#77/269 |
| Earnings Growth | 88.07% | US#378/3,111 Sec#15/269 |
| Financial Health | ||
| Debt Ratio | 152.88% | US#1,529/3,111 Sec#190/269 |
| Total Debt | $328M | US#2,030/3,111 Sec#72/269 |
| FCF | $160M | US#1,464/3,111 Sec#51/269 |
| Cash | $311M | US#1,396/3,111 Sec#78/269 |
| Current Ratio | 3.12x | US#768/3,111 Sec#192/269 |
| Net Debt/EBITDA | 0.07x | US#647/3,111 Sec#35/269 |
| Performance | ||
| 1Y Return | 25.22% | US#1,293/3,111 Sec#158/269 |
| 1M Return | -6.95% | US#2,072/3,111 Sec#145/269 |
| From 52W High | -19.55% | US#1,682/3,111 Sec#116/269 |
| 1Y MDD | -28.66% | US#1,275/3,111 Sec#80/269 |
| Trading | ||
| Volume | 362,946 shares | US#2,709/3,111 Sec#254/269 |
| Trading Value | $29M | US#2,159/3,111 Sec#171/269 |
| Per Share | ||
| EPS | $3.78 | US#821/3,111 Sec#23/269 |
| BPS | $26.96 | US#955/3,111 Sec#21/269 |
Company Info
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.